Guidelines for Treating Iron Overload in Myelodysplastic Syndromes: a Taiwan Consensus Statement

Overview

Journal Int J Hematol

Specialty Hematology

Date 2014 Jun 14

PMID 24924953

Citations 2

Authors

Bor-Sheng Ko

Cheng-Shyong Chang

Ming-Chih Chang

Tsai Yun Chen

Tzeon-Jye Chiou

Chang-Fang Chiu

Wen-Li Huang

Woei-Yau Kao

Yii-Jenq Lan

Shen-Fung Lin

Tran-Der Tan

Jih-Luh Tang

Cheng-Hwai Tzeng

Po-Nan Wang

Su-Pen Yet

Hwei-Fang Tien

Affiliations

Soon will be listed here.

Abstract

Iron overload is common in myelodysplastic syndrome (MDS) patients, and an accumulation of evidence shows that iron chelation may have benefits in these patients. However, discussion and consensus about iron chelation therapy (ICT) for MDS patients is lacking in Taiwan and other Southeast Asian countries. An Expert Panel in Taiwan was organized in 2011 to develop iron overload guidelines and provide a uniform reference for physicians treating MDS patients with iron overload, with specific regard to when to initiate ICT, in which patients, and the clinical and scientific rationale behind its use.

Citing Articles

Current treatment algorithm for the management of lower-risk MDS.

Giagounidis A Hematology Am Soc Hematol Educ Program. 2017; 2017(1):453-459.

PMID: 29222293 PMC: 6142548. DOI: 10.1182/asheducation-2017.1.453.

Status of Superoxide Dismutase in Transfusion Dependent Thalassaemia.

Rujito L, Mulatsih S, Sofro A N Am J Med Sci. 2015; 7(5):194-8.

PMID: 26110130 PMC: 4462814. DOI: 10.4103/1947-2714.157480.

References

List A . Iron overload in myelodysplastic syndromes: diagnosis and management. Cancer Control. 2010; 17 Suppl:2-8. DOI: 10.1177/107327481001701s01. View

Valent P, Krieger O, Stauder R, Wimazal F, Nosslinger T, Sperr W . Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur J Clin Invest. 2008; 38(3):143-9. PMC: 2438601. DOI: 10.1111/j.1365-2362.2007.01915.x. View

Goldberg S, Chen E, Corral M, Guo A, Mody-Patel N, Pecora A . Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010; 28(17):2847-52. DOI: 10.1200/JCO.2009.25.2395. View

Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M . Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007; 78(6):487-94. DOI: 10.1111/j.1600-0609.2007.00842.x. View

Olivieri N, Brittenham G . Iron-chelating therapy and the treatment of thalassemia. Blood. 1997; 89(3):739-61. View

Ma X, Does M, Raza A, Mayne S . Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007; 109(8):1536-42. DOI: 10.1002/cncr.22570. View

Malcovati L, Della Porta M, Pascutto C, Invernizzi R, Boni M, Travaglino E . Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005; 23(30):7594-603. DOI: 10.1200/JCO.2005.01.7038. View

Fischer R, Longo F, Nielsen P, Engelhardt R, Hider R, Piga A . Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol. 2003; 121(6):938-48. DOI: 10.1046/j.1365-2141.2003.04297.x. View

Malcovati L, Della Porta M, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K . Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011; 96(10):1433-40. PMC: 3186303. DOI: 10.3324/haematol.2011.044602. View

10.

Wells R, Leber B, Buckstein R, Lipton J, Hasegawa W, Grewal K . Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk Res. 2008; 32(9):1338-53. DOI: 10.1016/j.leukres.2008.02.021. View

11.

Meyer S, OMeara A, Buser A, Tichelli A, Passweg J, Stern M . Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2012; 19(3):440-4. DOI: 10.1016/j.bbmt.2012.10.012. View

12.

Ozyilmaz E, Aydogdu M, Sucak G, Aki S, Ozkurt Z, Yegin Z . Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload. Bone Marrow Transplant. 2010; 45(10):1528-33. DOI: 10.1038/bmt.2009.383. View

13.

Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y . Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox. Free Radic Biol Med. 2012; 53(4):643-8. DOI: 10.1016/j.freeradbiomed.2012.06.006. View

14.

Jensen P, Heickendorff L, Pedersen B, Jensen F, Christensen T, Boesen A . The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996; 94(2):288-99. DOI: 10.1046/j.1365-2141.1996.d01-1795.x. View

15.

Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N . Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One. 2011; 6(8):e23109. PMC: 3158762. DOI: 10.1371/journal.pone.0023109. View

16.

Mittelman M, Lugassy G, Merkel D, Tamary H, Sarid N, Rachmilewitz E . Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines. Isr Med Assoc J. 2008; 10(5):374-6. View

17.

Cazzola M, Della Porta M, Malcovati L . Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2008; :166-75. DOI: 10.1182/asheducation-2008.1.166. View

18.

Porter J, Bowden D, Economou M, Troncy J, Ganser A, Habr D . Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial. Anemia. 2012; 2012:297641. PMC: 3424665. DOI: 10.1155/2012/297641. View

19.

Cheong J, Kim H, Lee K, Yoon S, Lee J, Park H . Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia. Transfusion. 2013; 54(6):1542-51. DOI: 10.1111/trf.12507. View

20.

Wood J, Enriquez C, Ghugre N, Otto-Duessel M, Aguilar M, Nelson M . Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci. 2005; 1054:386-95. PMC: 2892916. DOI: 10.1196/annals.1345.047. View